Welcome to: Beijing Dongfang Baitai Biotechnology Co., Ltd.

Double joy! The adalimumab biosimilar from Dongfang Baitai has received clinical trial approval!


[Summary Description]

Within half a month, two products of Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as “Dongfang Baitai”)—the humanized anti‑vascular endothelial growth factor (VEGF) antibody drug JY028 and the fully human anti‑tumor necrosis factor‑α (TNF‑α) antibody drug JY026—have successively obtained clinical trial approvals from the China Food and Drug Administration (CFDA), marking a double celebration! At present, the company has three drug candidates—JY09, JY028, and JY026—that have entered clinical development.


Recommended News

Leave a Message Online Online Message


Submit